The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study.

Abstract:

BACKGROUND:The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS:Patients with glycated hemoglobin (HbA1c) levels of ≥8% (64 mmol/mol) and ≤12% (108 mmol/mol) despite insulin doses of 0.7-1.8 U/kg/day via MDI were randomized to CSII (n=168) or continued MDI (n=163). Changes in glucose profiles were evaluated using continuous glucose monitoring data collected over 6-day periods before and 6 months after randomization. RESULTS:After 6 months, reductions in HbA1c levels were significantly greater with CSII (-1.1±1.2% [-12.0±13.1 mmol/mol]) than with MDI (-0.4±1.1% [-4.4±12.0 mmol/mol]) (P<0.001). Similarly, compared with patients receiving MDI, those receiving CSII showed significantly greater reductions in 24-h mean sensor glucose (SG) (treatment difference, -17.1 mg/dL; P=0.0023), less exposure to SG >180 mg/dL (-12.4%; P=0.0004) and SG >250 mg/dL (-5.5%; P=0.0153), and more time in the SG range of 70-180 mg/dL (12.3%; P=0.0002), with no differences in exposure to SG<70 mg/dL or in glucose variability. Changes in postprandial (4-h) glucose area under the curve >180 mg/dL were significantly greater with CSII than with MDI after breakfast (-775.9±1,441.2 mg/dL/min vs. -160.7±1,074.1 mg/dL/min; P=0.0015) and after dinner (-731.4±1,580.7 mg/dL/min vs. -71.1±1,083.5 mg/dL/min; P=0.0014). CONCLUSIONS:In patients with suboptimally controlled type 2 diabetes, CSII significantly improves selected glucometrics, compared with MDI, without increasing the risk of hypoglycemia.

journal_name

Diabetes Technol Ther

authors

Conget I,Castaneda J,Petrovski G,Guerci B,Racault AS,Reznik Y,Cohen O,Runzis S,de Portu S,Aronson R,OpT2mise Study Group.

doi

10.1089/dia.2015.0159

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

22-8

issue

1

eissn

1520-9156

issn

1557-8593

journal_volume

18

pub_type

杂志文章,随机对照试验
  • Daily glucose profiles in Japanese people with normal glucose tolerance as assessed by continuous glucose monitoring.

    abstract:BACKGROUND:Little information is available regarding glucose fluctuations in postprandial states and during the oral glucose tolerance test (OGTT) in Japanese people with normal glucose tolerance (NGT). METHODS:Glucose profiles of 27 Japanese people were measured for 4 days by using continuous glucose monitoring. A 75...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2008.0083

    authors: Tsujino D,Nishimura R,Taki K,Miyashita Y,Morimoto A,Tajima N

    更新日期:2009-07-01 00:00:00

  • Continuous glucose monitoring reveals delayed nocturnal hypoglycemia after intermittent high-intensity exercise in nontrained patients with type 1 diabetes.

    abstract:OBJECTIVE:Exercise is a cornerstone of diabetes therapy in type 1 diabetes mellitus (DMT1) patients. The type of exercise is important in determining the propensity to hypoglycemia. We assessed, by continuous glucose monitoring (CGM), the glucose profiles during and in the following 20h after a session of two different...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1089/dia.2010.0038

    authors: Maran A,Pavan P,Bonsembiante B,Brugin E,Ermolao A,Avogaro A,Zaccaria M

    更新日期:2010-10-01 00:00:00

  • "Glucometrics"--assessing the quality of inpatient glucose management.

    abstract:BACKGROUND:For patients with diabetes, the quality of outpatient glycemic control is readily assessed by hemoglobin A1c. In contrast, standardized measures for assessing the quality of blood glucose (BG) management in hospitalized patients are lacking. Because of recent studies demonstrating the benefits of strict glyc...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2006.8.560

    authors: Goldberg PA,Bozzo JE,Thomas PG,Mesmer MM,Sakharova OV,Radford MJ,Inzucchi SE

    更新日期:2006-10-01 00:00:00

  • Analysis of continuous glucose monitoring data from non-diabetic and diabetic children: a tale of two algorithms.

    abstract::Use of the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in non-diabetic children has revealed many low and high sensor glucose (SG) values, suggesting that the original analytical algorithm (Solutions 2.0) might be overreading glycemic excursions. A revised algorithm (Solutions 3.0) was introduced in ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091503765691866

    authors: Weinzimer SA,DeLucia MC,Boland EA,Steffen A,Tamborlane WV

    更新日期:2003-01-01 00:00:00

  • NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes.

    abstract:BACKGROUND:Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the diagnostic performance of NerveCheck, an inexpensive ($500) quantitative sensory testing (QST) device....

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2016.0279

    authors: Ponirakis G,Odriozola MN,Odriozola S,Petropoulos IN,Azmi S,Ferdousi M,Fadavi H,Alam U,Marshall A,Jeziorska M,Miro A,Kheyami A,Tavakoli M,Al-Ahmar A,Odriozola MB,Odriozola A,Malik RA

    更新日期:2016-12-01 00:00:00

  • Cutaneous blood perfusion as a perturbing factor for noninvasive glucose monitoring.

    abstract::It is widely accepted that noninvasive glucose monitoring (NIGM) has the potential to revolutionize diabetes therapy. However, current approaches to NIGM studied to date have not yet demonstrated a level of acceptable functionality to allow real-time use, beyond restricted fields of application. A number of reviews ha...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2009.0095

    authors: Caduff A,Talary MS,Zakharov P

    更新日期:2010-01-01 00:00:00

  • Clinical predictors of glycosylated hemoglobin response to thiazolidinedione therapy.

    abstract:BACKGROUND:The aim of this investigation was to assess clinical predictors of the glycosylated hemoglobin (HbA1C) response after the addition of a thiazolidinedione (TZD) to a biguanide, a sulfonylurea, or both in subjects with type 2 diabetes. METHODS:Chart review (n = 68 physicians) was used to identify consecutive ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2007.0248

    authors: Izumi R,Hurt J,Maki KC,Bell M,Zavras AI,McCamish M

    更新日期:2007-12-01 00:00:00

  • Role of continuous subcutaneous insulin infusion in patients with recalcitrant diabetes in South India.

    abstract:BACKGROUND:We aimed to assess the effect of continuous subcutaneous insulin infusion (CSII) therapy in patients with "recalcitrant diabetes" whose glycemia had not been controlled adequately with multiple daily injections of insulin or insulin plus oral hypoglycemic agents. PATIENTS AND METHODS:We retrospectively anal...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0066

    authors: Sudhakaran C,Anjana RM,Rao K,Unnikrishnan R 1st,Suresh T,Mohan V

    更新日期:2009-11-01 00:00:00

  • Time is glucose, can't miss gestational diabetes.

    abstract:BACKGROUND:Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes, if not treated. International guidelines recommend screening "all or high-risk women" at the initial prenatal visit, when a fasting plasma glucose (FPG) between 92 and 126 mg/dL is diagnostic for GDM. However, glucose testing ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0225

    authors: Festa R,Carta M,Ceriello A,Testa R

    更新日期:2012-05-01 00:00:00

  • Perioperative Characteristics of the Accuracy of Subcutaneous Continuous Glucose Monitoring: Pilot Study in Neurosurgery and Cardiac Surgery.

    abstract:BACKGROUND:The aim of this study was to elucidate the characteristics of accuracy of subcutaneous continuous glucose monitoring (SCGM) in the perioperative period for neurosurgical and cardiac surgery patients. METHODS:Forty-five subjects, including healthy volunteers (n = 15), neurosurgical patients (n = 15), and car...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0140

    authors: Sugiyama Y,Wakabayashi R,Urasawa M,Maruyama Y,Shimizu S,Kawamata M

    更新日期:2018-10-01 00:00:00

  • Combining basal insulin analogs with glucagon-like peptide-1 mimetics.

    abstract::Basal insulin analogs are recognized as an effective method of achieving and maintaining glycemic control for patients with type 2 diabetes. However, the progressive nature of the disease means that some individuals may require additional ways to maintain their glycemic goals. Intensification in these circumstances ha...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2010.0250

    authors: Perfetti R

    更新日期:2011-09-01 00:00:00

  • Interactive educational diabetes/insulin tutorial at www.2aida.info.

    abstract::The World Wide Web now hosts a multitude of diabetes educational materials in various formats. Of particular interest is the diabetes/insulin tutorial available at the AIDA Website (accessible directly at: www.2aida.info). The tutorial combines textual or "static" information with an interactive diabetes simulator-AID...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2006.8.126

    authors: Reed K,Lehmann ED

    更新日期:2006-02-01 00:00:00

  • Is the masked continuous glucose monitoring system clinically useful for predicting hemoglobin A1C in type 1 diabetes?

    abstract:BACKGROUND:The masked continuous glucose monitoring system (Masked-CGMS) differs from standard CGMSs in three ways: (1) there is no feedback to the user so that no immediate regimen changes can be made; (2) it can only be worn for up to 5 days; and (3) there are no alarms to warn of hyperglycemia or hypoglycemia. Since...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2013.0297

    authors: Duran-Valdez E,Burge MR,Broderick P,Shey L,Valentine V,Schrader R,Schade DS

    更新日期:2014-05-01 00:00:00

  • The Impact of Short-Term Professional Continuous Glucose Monitoring on Glycemic Control Via Lifestyle Improvement.

    abstract:BACKGROUND:The efficacy of short-term professional continuous glucose monitoring (CGM) for glycemic control in patients with diabetes remains unclear. METHODS:We performed a 3-month study to evaluate the benefits of CGM in 64 patients. RESULTS:The overall glycemic control of patients who underwent CGM improved signif...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0164

    authors: Shibusawa R,Yamada E,Okada S,Nakajima Y,Bastie CC,Yamada M

    更新日期:2018-09-01 00:00:00

  • Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes.

    abstract:BACKGROUND:Improved insulin infusion set survival and faster insulin action are important issues for pump users and for the development of an artificial pancreas. The current recommendation is to change infusion sets every 3 days. Our objectives were to determine the effect of lipohypertrophy (LH) on infusion set survi...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2015.0432

    authors: Karlin AW,Ly TT,Pyle L,Forlenza GP,Messer L,Wadwa RP,DeSalvo DJ,Payne SL,Hanes S,Clinton P,Maahs DM,Buckingham B

    更新日期:2016-07-01 00:00:00

  • Reviewing U.S. Connected Diabetes Care: The Newest Member of the Team.

    abstract::Recent years have brought about an explosion in the number of companies offering connected diabetes care products, defined as digital diabetes management systems based around (1) smartphone apps, (2) devices with built-in connectivity, and (3) remote human and automated coaching and support. These nascent models aim t...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2019.0273

    authors: Levine BJ,Close KL,Gabbay RA

    更新日期:2020-01-01 00:00:00

  • The Effectiveness of Continuous Glucose Monitoring in Patients with Type 2 Diabetes: A Systematic Review of Literature and Meta-analysis.

    abstract:BACKGROUND:Continuous glucose monitoring (CGM) provides glucose trend information that can be used to guide treatment and motivate patients with diabetes. Currently, the evidence on effectiveness of CGM in patients with type 2 diabetes is debatable. We aim to provide a systematic review and meta-analysis to synthesize ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1089/dia.2018.0177

    authors: Park C,Le QA

    更新日期:2018-09-01 00:00:00

  • Evaluation of a Nurse-Managed Insulin Infusion Protocol.

    abstract:BACKGROUND:The purpose of this study was to evaluate the performance of an insulin infusion protocol targeting a blood glucose (BG) level of 140-180 mg/dL and to characterize protocol adherence. MATERIALS AND METHODS:This was a retrospective observational cohort study including patients for whom the protocol was order...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2015.0046

    authors: Passarelli AJ,Gibbs H,Rowden AM,Efird L,Zink E,Mathioudakis N

    更新日期:2016-02-01 00:00:00

  • Where Do We Stand with Closed-Loop Systems and Their Challenges?

    abstract::Treatments for type 1 diabetes have advanced significantly over recent years. There are now multiple hybrid closed-loop systems commercially available and additional systems are in development. Challenges remain, however. This review outlines the recent advances in closed-loop systems and outlines the remaining challe...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0469

    authors: Jackson M,Castle JR

    更新日期:2020-07-01 00:00:00

  • A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patients.

    abstract:BACKGROUND:This article reports a prolonged trial with insulin pumps implanted in patients with type 1 diabetes showing poor glucose control and a high rate of complications. METHODS:We reviewed data from 181 patients undergoing implanted insulin pump therapy. Analysis included hemoglobin A1c (HbA1c) values, body weig...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0209

    authors: Schaepelynck P,Renard E,Jeandidier N,Hanaire H,Fermon C,Rudoni S,Catargi B,Riveline JP,Guerci B,Millot L,Martin JF,Sola A,EVADIAC Group.

    更新日期:2011-06-01 00:00:00

  • Regulatory aspects of invasive glucose measurements.

    abstract::On May 26, 1976, the Food and Drug Administration (FDA) began implementing the Medical Device Amendments to the Federal Food Drug and Cosmetic Act. These amendments give FDA specific authority to regulate "medical devices." Additional authority was provided in the Safe Medical Devices Act of 1990. The pathways to get ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091502321118784

    authors: Gutman S,Bernhardt P,Pinkos A,Moxey-Mims M,Knott T,Cooper J

    更新日期:2002-01-01 00:00:00

  • Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting.

    abstract::Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have be...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2017.0054

    authors: Schnell O,Barnard K,Bergenstal R,Bosi E,Garg S,Guerci B,Haak T,Hirsch IB,Ji L,Joshi SR,Kamp M,Laffel L,Mathieu C,Polonsky WH,Snoek F,Home P

    更新日期:2017-07-01 00:00:00

  • Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.

    abstract::It is becoming increasingly acknowledged that people with Type 2 Diabetes represent what can be termed "an enriched population": a group that has the greatest risk of morbidity and mortality from cardiovascular diseases such as myocardial infarcts and strokes. Due to the tremendous toll, both human and financial, that...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/15209150050025258

    authors: Marcus AO

    更新日期:2000-07-01 00:00:00

  • A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II.

    abstract:BACKGROUND:Persistent use of real-time continuous glucose monitoring (CGM) improves diabetes control in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D). METHODS:PRECISE II was a nonrandomized, blinded, prospective, single-arm, multicenter study that evaluated the accuracy and safety of the implantable...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2017.0142

    authors: Christiansen MP,Klaff LJ,Brazg R,Chang AR,Levy CJ,Lam D,Denham DS,Atiee G,Bode BW,Walters SJ,Kelley L,Bailey TS

    更新日期:2018-03-01 00:00:00

  • Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.

    abstract:BACKGROUND:Drugs with unspecific stimulating effects on beta-cell secretion increase the homeostasis model assessment (HOMA)-B score, indicating improved beta-cell "function." We investigated whether the beta-cell protection provided by adding pioglitazone (PIO) to glimepiride (GLIM) in comparison to up-titrating the G...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2010.0019

    authors: Pfützner A,Derwahl M,Jacob S,Hohberg C,Blümner E,Lehmann U,Fuchs W,Forst T

    更新日期:2010-08-01 00:00:00

  • Overcoming skin's barrier: the search for effective and user-friendly drug delivery.

    abstract::Although hypodermic needles rapidly deliver large doses of drugs such as insulin across the skin for systemic administration, the pain, local trauma, and difficulty to achieve sustained or complex delivery profiles has motivated development of novel alternative technologies. Microneedles, jet injectors, and thermal po...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/152091501300209606

    authors: Prausnitz MR

    更新日期:2001-07-01 00:00:00

  • Randomized Evaluation of Glycemic Control in the Medical Intensive Care Unit Using Real-Time Continuous Glucose Monitoring (REGIMEN Trial).

    abstract:BACKGROUND AND OBJECTIVE:Hyperglycemia occurs commonly in patients admitted to medical intensive care units (MICUs). Whether real-time (RT) continuous glucose monitoring (CGM) improves glycemic control and variability and reduces hypoglycemia in severely ill MICU patients with an Acute Physiology and Chronic Health Eva...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2015.0151

    authors: De Block CE,Gios J,Verheyen N,Manuel-y-Keenoy B,Rogiers P,Jorens PG,Scuffi C,Van Gaal LF

    更新日期:2015-12-01 00:00:00

  • Improved glycemic control after long-term insulin pump use in pediatric patients with type 1 diabetes.

    abstract:BACKGROUND:There are currently few data available on the long-term use of continuous subcutaneous insulin infusion (CSII) (insulin pump) therapy in children. METHODS:Charts from 291 youth with type 1 diabetes (T1D) who were treated with CSII therapy for at least 1 year were reviewed. Data analysis included hemoglobin ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2007.0214

    authors: Scrimgeour L,Cobry E,McFann K,Burdick P,Weimer C,Slover R,Chase HP

    更新日期:2007-10-01 00:00:00

  • Adiponectin and carotid intimal medial thickness in subjects with and without glucose intolerance (CURES-82).

    abstract:OBJECTIVE:This study assessed the association of serum adiponectin with carotid intimal medial thickness (IMT) in Asian Indians with different grades of glucose intolerance. METHODS:Subjects with normal glucose tolerance (NGT) (n = 520), impaired glucose tolerance (IGT) (n = 115), and type 2 diabetes mellitus (T2DM) (...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0100

    authors: Gokulakrishnan K,Indulekha K,Ganesan S,Anuradha S,Mohan V

    更新日期:2010-02-01 00:00:00

  • High Glucose Variability in Hospitalized Patients with Type 1 Diabetes Mellitus.

    abstract:BACKGROUND:Glucose variability (GV) has been increasingly (or more extensively) studied in patients with type 1 diabetes (T1D) in the ambulatory setting; limited data exist on GV in hospitalized patients with T1D. MATERIALS AND METHODS:Retrospective single center cohort study, we analyzed in-hospital glucose measureme...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2017.0107

    authors: Dadlani V,Tamhane SU,Sun A,Sharma A,Delivanis DA,Thapa P,Carter RE,Kudva YC

    更新日期:2017-10-01 00:00:00